AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 11, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Non-squamous NSCLC
Interventions
DRUG

Afatinib

Afatinib followed by osimertinib or ICT

DRUG

Osimertinib

Osimertinib followed by ICT

Trial Locations (11)

13125

Evangelische Lungenklinik Berlin, Berlin

20251

Studiengesellschaft Hämato-Onkologie Hamburg, Hamburg

28325

Klinikum Bremen-Ost, Bremen

35392

Universitätsklinikum Gießen Marburg, Giessen

59063

Evangelisches Krankenhaus Hamm, Hamm

63069

Sana-Klinikum Offenbach, Offenbach

74245

Klinik Löwenstein gGmbH, Löwenstein

78464

Gemeinnützige Krankenhausbetriebsgesellschaft Konstanz Mbh, Konstanz

80336

Klinikum der Ludwig-Maximilians-Universität München, München

87509

Klinikverbund Allgäug gGmbH, Klinik für Pneumologie, c/o Klinik, Immenstadt im Allgäu

93053

Universitätsklinikum Regensburg, Regensburg

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Michael Hopp

OTHER